Autoimmune Response to Post-Translationally Modified (Citrullinated) Proteins: Prime Suspect in the Pathophysiology of Rheumatoid Arthritis

The Epigenetics of Autoimmune Diseases

Volumn , Issue , 2009, Pages 279-308

  Sebbag, Mireille ^a   Clavel, Cyril ^a,b   Nogueira, Leonor ^a,b   Arnaud, Jacques ^a   Serre, Guy ^a,b  

^a CNRS   (France)

^b CHU PURPAN   (France)

Author keywords

ACPA, promoting joint inflammation; Anti keratin antibodies; Anti perinuclear factor; Autoimmune response to post translationally modified (citrullinated) proteins; Citrullinated vimentin; Epstein Barr virus (EBV); RA, associating with B cell autoreactivity; Rheumatoid arthritis (RA), affecting 0.5 1 of world's adult population

Indexed keywords

EID: 79951910507     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470743553.ch16     Document Type: Chapter

References (183)

1. Nienhuis, R.L.F. and Mandema, E. (1964) A new serum factor in patients with rheumatoid arthritis: the antiperinuclear factor. Annals of the Rheumatic Diseases 23, 302-305.
2. Sebbag, M., Simon, M., Vincent, C. et al. (1995) The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. Journal of Clinical Investigation 95, 2672-2679.
3. Young, B.J., Mallya, R.K., Leslie, R.D. et al. (1979) Anti-keratin antibodies in rheumatoid arthritis. British Medical Journal 2, 97-99.
4. Girbal, E., Sebbag, M., Gomes-Daudrix, V. et al. (1993) Characterisation of the rat oesophagus epithelium antigens defined by the so-called 'antikeratin antibodies', specific for rheumatoid arthritis. Annals of the Rheumatic Diseases 52, 749-757.
5. Simon, M., Girbal, E., Sebbag, M. et al. (1993) The cytokeratin filament-aggregating protein filaggrin is the target of the so-called "antikeratin antibodies," autoantibodies specific for rheumatoid arthritis. Journal of Clinical Investigation 92, 1387-1393.
6. Chavanas, S., Mechin, M.C., Nachat, R. etal. (2006) Peptidylarginine deiminases and deimina-tion in biology and pathology: relevance to skin homeostasis. Journal of Dermatological Science 44, 63-72.
7. Mechin, M.C., Sebbag, M., Arnaud, J. et al. (2007) Update on peptidylarginine deiminases and deimination in skin physiology and severe human diseases. International Journal of Cosmetic Science 29, 147-168.
8. Nachat, R., Mechin, M.C., Charveron, M. etal. (2005) Peptidylarginine deiminase isoforms are differentially expressed in the anagen hair follicles and other human skin appendages. Journal of Investigative Dermatology 125, 34-41.
9. Nachat, R., Mechin, M.C., Takahara, H. et al. (2005) Peptidylarginine deiminase isoforms 1-3 are expressed in the epidermis and involved in the deimination of K1 and filaggrin. Journal of Investigative Dermatology 124, 384-393.
10. Urano, Y., Watanabe, K., Sakaki, A. et al. (1990) Immunohistochemical demonstration of peptidylarginine deiminase in human sweat glands. American Journal of Dermatopathology 12, 249-255.
11. Ishigami, A., Ohsawa, T., Asaga, H. et al. (2002) Human peptidylarginine deiminase type II: molecular cloning, gene organization, and expression in human skin. Archives of Biochemistry and Biophysics 407, 25-31.
12. Sambandam, T., Belousova, M., Accaviti-Loper, M.A. et al. (2004) Increased peptidylarginine deiminase type II in hypoxic astrocytes. Biochemical and Biophysical Research, Communications 325, 1324-1329.
13. Ishigami, A., Ohsawa, T., Hiratsuka, M. et al. (2005) Abnormal accumulation of citrullinated proteins catalyzed by peptidylarginine deiminase in hippocampal extracts from patients with Alzheimer's disease. Journal of Neuroscience Research 80, 120-128.
14. Vossenaar, E.R., Radstake, T.R., van der Heijden, A. et al. (2004) Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages. Annals of the Rheumatic Diseases 63, 373-381.
15. Kanno, T., Kawada, A., Yamanouchi, J. etal. (2000) Human peptidylarginine deiminase type III: molecular cloning and nucleotide sequence of the cDNA, properties of the recombinant enzyme, and immunohistochemical localization in human skin. Journal of InvestigativeDermatology 115, 813-823.
16. Mechin, M.C., Enji, M., Nachat, R. et al. (2005) The peptidylarginine deiminases expressed in human epidermis differ in their substrate specificities and subcellular locations. Cellular and Molecular Life Sciences 62, 1984-1995.
17. Nakashima, K., Hagiwara, T., Ishigami, A. et al. (1999) Molecular characterization of pepti-dylarginine deiminase in HL-60 cells induced by retinoic acid and 1alpha,25-dihydroxyvitamin D(3). Journal of Biological Chemistry 274, 27786-27792.
18. Asaga, H., Nakashima, K., Senshu, T. et al. (2001) Immunocytochemical localization of peptidylarginine deiminase in human eosinophils and neutrophils. Journal of Leukocyte Biology 70, 46-51.
19. Chang, X., Yamada, R., Suzuki, A. et al. (2005) Localization of peptidylarginine deiminase 4 (PAD14) and citrullinated protein in synovial tissue of rheumatoid arthritis. Rheumatology (Oxford) 44, 40-50.
20. Foulquier, C., Sebbag, M., Clavel, C. et al. (2007) Peptidyl arginine deiminase type 2 (PAD-2) and PAD-4 but not PAD-1, PAD-3, and PAD-6 are expressed in rheumatoid arthritis synovium in close association with tissue inflammation. Arthritis and Rheumatism 56, 3541-3553.
21. Wright, P.W., Bolling, L.C., Calvert, M.E. et al. (2003) ePAD, an oocyte and early embryo-abundant peptidylarginine deiminase-like protein that localizes to egg cytoplasmic sheets. Developmental Biology 256, 73-88.
22. Inagaki, M., Takahara, H., Nishi, Y. et al. (1989) Ca2 +-dependent deimination-induced disassembly ofintermediate filaments involves specific modification of the amino-terminal head domain. Journal of Biological Chemistry 264, 18119-18127.
23. Tarcsa, E., Marekov, L.N., Mei, G. etal. (1996) Protein unfolding by peptidylarginine deiminase. Substrate specificity and structural relationships of, the natural substrates trichohyalin and filaggrin. Journal of Biological Chemistry 271, 30709-30716.
24. Gyorgy, B., Toth, E., Tarcsa, E. et al. (2006) Citrullination: a posttranslational modification in health and disease. International Journal of Biochemistry & Cell, Biology 38, 1662-1677.
25. Senshu, T., Kan, S., Ogawa, H. etal. (1996) Preferential deimination of keratin K1 and filaggrin during the terminal differentiation of human epidermis. Biochemical and Biophysical Research, Communications 225, 712-719.
26. Moscarello, M.A., Wood, D.D., Ackerley, C. and Boulias, C. (1994) Myelin in multiple sclerosis is developmentally immature. Journal of Clinical Investigation 94, 146-154.
27. Harauz, G. and Musse, A.A. (2007) A tale of two citrullines-structural and functional aspects of myelin basic protein deimination in health and disease. Neurochemical Research 32, 137-158.
28. Liu, M., Oh, A., Calarco, P. et al. (2005) Peptidylarginine deiminase (PAD) is a mouse cortical granule protein that plays a role liu. Reproductive Biology and Endocrinology 3, 42.
29. Esposito, G., Vitale, A.M., Leijten, F.P. et al. (2007) Peptidylarginine deiminase (PAD) 6 is essential for oocyte cytoskeletal sheet formation and female fertility. Molecular and Cellular Endocrinology 273, 25-31.
30. Cuthbert, G.L., Daujat, S., Snowden, A.W. et al. (2004) Histone deimination antagonizes arginine methylation. Cell 118, 545-553.
31. Wang, Y., Wysocka, J., Sayegh, J. et al. (2004) Human PAD4 regulates histone arginine methylation levels via demethylimination. Science 306, 279-283.
32. Raijmakers, R., Zendman, A.J., Egberts, W.V. et al. (2007) Methylation of arginine residues interferes with citrullination by peptidylarginine deiminases in vitro. Journal of Molecular Biology 367, 1118-1129.
33. Girbal-Neuhauser, E., Durieux, J.J., Arnaud, M. et al. (1999) The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues. Journal of Immunology 162, 585-594.
34. Schellekens, G.A., de Jong, B.A., van den Hoogen, F.H. et al. (1998) Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoanti-bodies. Journal of Clinical Investigation 101, 273-281.
35. Senshu, T., Akiyama, K., Kan, S. et al. (1995) Detection of deiminated proteins in rat skin: probing with a monospecific antibody after modification of citrulline residues. Journal of Investigative Dermatology 105, 163-169.
36. Union, A., Meheus, L., Humbel, R.L. et al. (2002) Identification of citrullinated rheumatoid arthritis-specific epitopes in natural filaggrin relevant for antifilaggrin autoantibody detection by line immunoassay. Arthritis and Rheumatism 46, 1185-1195.
37. Sondag-Tschroots, I.R., Aaij, C., Smit, J.W. and Feltkamp, T.E. (1979) The antiperinuclear factor. 1. The diagnostic significance of the antiperinuclear factor for rheumatoid arthritis. Annals of the Rheumatic Diseases 38, 248-251.
38. Johnson, G.D., Carvalho, A., Holborow, E.J. et al. (1981) Antiperinuclear factor and keratin antibodies in rheumatoid arthritis. Annals of the Rheumatic Diseases 40, 263-266.
39. Mallya, R.K., Young, B.J., Pepys, M.B. et al. (1983) Anti-keratin antibodies in rheumatoid arthritis: frequency and correlation with other features of the disease. Clinical and Experimental Immunology 51, 17-20.
40. Ordeig, J. and Guardia, J. (1984) Diagnostic value of antikeratin antibodies in rheumatoid arthritis. Journal of Rheumatology 11, 602-604.
41. Hajiroussou, V.J., Skingle, J., Gillett, A.P. and Webley, M. (1985) Significance of antikeratin antibodies in rheumatoid arthritis. Journal of Rheumatology 12, 57-59.
42. Youinou, P., Le Goff, P., Colaco, C.B. etal. (1985) Antikeratinantibodies in serum and synovial fluid show specificity for rheumatoid arthritis in a study of connective tissue diseases. Annals of the Rheumatic Diseases 44, 450-454.
43. Kirstein, H. and Mathiesen, F.K. (1987) Antikeratin antibodies in rheumatoid arthritis. Methods and clinical significance. Scandinavian Journal of Rheumatology 16, 331-338.
44. Janssens, X., Veys, E.M., Verbruggen, G. and Declercq, L. (1988) The diagnostic significance of the antiperinuclear factor for rheumatoid arthritis. Journal of Rheumatology 15, 1346-1350.
45. Vincent, C., Serre, G., Lapeyre, F. et al. (1989) High diagnostic value in rheumatoid arthritis of antibodies to the stratum corneum of rat oesophagus epithelium, so-called 'antikeratin antibodies'. Annals of the Rheumatic Diseases 48, 712-722.
46. Youinou, P., Le Goff, P., Dumay, A. et al. (1990) The antiperinuclear factor. I. Clinical and serologic associations. Clinical and Experimental Rheumatology 8, 259-264.
47. von Essen, R., Kurki, P., Isomaki, H. etal. (1993) Prospect for an additional laboratory criterion for rheumatoid arthritis. Scandinavian Journal of Rheumatology 22, 267-272.
48. Vincent, C., Nogueira, L., Clavel, C. etal. (2005) Autoantibodies to citrullinated proteins: ACPA. Autoimmunity 38, 17-24.
49. Schellekens, G.A., Visser, H., de Jong, B.A. etal. (2000) The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis and Rheumatism 43, 155-163.
50. Coenen, D., Verschueren, P., Westhovens, R. and Bossuyt, X. (2007) Technical and diagnostic performance of 6 assays for the measurement of citrullinated protein/peptide antibodies in the diagnosis of rheumatoid arthritis. Clinical Chemistry 53, 498-504.
51. Masson-Bessiere, C., Sebbag, M., Durieux, J.J. et al. (2000) In the rheumatoid pannus, anti-filaggrin autoantibodies are produced by local plasma cells and constitute a higher proportion of IgGs than in synovial fluid and serum. Clinical and Experimental Immunology 119, 544-552.
52. Iwaki-Egawa, S., Matsuno, H., Ogawa, Y. and Watanabe, Y. (2005) Production of anti-CCP antibodies and matrix metalloproteinase-3 by human rheumatoid arthritis synovial tissues using SCID mice. Annals of the Rheumatic Diseases 64, 1094-1095.
53. Masson-Bessiere, C., Sebbag, M., Girbal-Neuhauser, E. etal. (2001) The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha-and beta-chains of fibrin. Journal of Immunology 166, 4177-4184.
54. Chapuy-Regaud, S., Sebbag, M., Baeten, D. etal. (2005) Fibrin deimination in synovial tissue is not specific for rheumatoid arthritis but commonly occurs during synovitides. Journal of Immunology 174, 5057-5064.
55. Edwards, J.C. and Cambridge, G. (2006) B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nature Reviews Immunology 6, 394-403.
56. Petkova, S.B., Konstantinov, K.N., Sproule, T.J. et al. (2006) Human antibodies induce arthritis in mice deficient in the low-affinity inhibitory IgGs receptor Fc gamma RIIB. Journal of Experimental Medicine 203, 275-280.
57. Paimela, L., Gripenberg, M., Kurki, P. and Leirisalo-Repo, M. (1992) Antikeratin antibodies: diagnostic and prognostic markers for early rheumatoid arthritis. Annals of the Rheumatic Diseases 51, 743-746.
58. Berthelot, J.M., Maugars, Y., Castagne, A. et al. (1997) Antiperinuclear factors are present in polyarthritis before ACR criteria for rheumatoid arthritis are fulfilled. Annals of the Rheumatic Diseases 56, 123-125.
59. Goldbach-Mansky, R., Lee, J., McCoy, A. et al. (2000) Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Research 2, 236-243.
60. Paimela, L., Palosuo, T., Aho, K. et al. (2001) Association of autoantibodies to filaggrin with an active disease in early rheumatoid arthritis. Annals of the Rheumatic Diseases 60, 32-35.
61. Jansen, A.L., van der Horst-Bruinsma, I., van Schaardenburg, D. et al. (2002) Rheumatoid factor and antibodies to cyclic citrullinated Peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis. Journal of Rheumatology 29, 2074-2076.
62. van Gaalen, F.A., Linn-Rasker, S.P., van Venrooij, W.J. et al. (2004) Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferenti-ated arthritis: a prospective cohort study. Arthritis and Rheumatism 50, 709-715.
63. Kastbom, A., Strandberg, G., Lindroos, A. and Skogh, T. (2004) Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Annals of the Rheumatic Diseases 63, 1085-1089.
64. Nielen, M.M., van der Horst, A.R., van Schaardenburg, D. et al. (2005) Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis. Annals of the Rheumatic Diseases 64, 1199-1204.
65. Raza, K., Breese, M., Nightingale, P. et al. (2005) Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis. Journal of Rheumatology 32, 231-238.
66. Quinn, M.A., Gough, A.K., Green, M.J. et al. (2006) Anti-CCP antibodies measured at disease onset help, identify seronegative rheumatoid arthritis and predict radiological and functional outcome. Rheumatology (Oxford) 45, 478-480.
67. Vander Cruyssen, B., Cantaert, T., Nogueira, L. et al. (2006) Diagnostic value of anti-human citrullinated fibrinogen ELISA and comparison with four other anti-citrullinated protein assays. Arthritis Research and Therapy 8, R122.
68. Machold, K.P., Stamm, T.A., Nell, V.P. et al. (2007) Very recent onset rheumatoid arthritis: clinical and, serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology (Oxford) 46, 342-349.
69. Ates, A., Karaaslan, Y. and Aksaray, S. (2007) Predictive value of antibodies to cyclic citrullinated peptide in patients with early arthritis. Clinical Rheumatology 26, 499-504.
70. Kurki, P., Aho, K., Palosuo, T. and Heliovaara, M. (1992) Immunopathology of rheumatoid arthritis. Antikeratin antibodies precede the clinical disease. Arthritis and Rheumatism 35, 914-917.
71. Rantapaa-Dahlqvist, S., de Jong, B.A., Berglin, E. et al. (2003) Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis and Rheumatism 48, 2741-2749.
72. Nielen, M.M., van Schaardenburg, D., Reesink, H.W. et al. (2004) Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis and Rheumatism 50, 380-386.
73. Berglin, E., Padyukov, L., Sundin, U. et al. (2004) A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis. Arthritis Research and Therapy 6, R303-R308.
74. Meyer, O., Combe, B., Elias, A. et al. (1997) Autoantibodies predicting the outcome of rheumatoid arthritis: evaluation in two subsets of patients according to severity of radiographic damage. Annals of the Rheumatic Diseases 56, 682-685.
75. Hayem, G., Chazerain, P., Combe, B. etal. (1999) Anti-Sa antibody is an accurate diagnostic and prognostic marker in adult rheumatoid arthritis. Journal of Rheumatology 26, 7-13.
76. De Rycke, L., Peene, I., Hoffman, I.E.A. et al. (2004) Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Annals of the Rheumatic Diseases 63, 1587-1593.
77. Bongi, S.M., Manetti, R., Melchiorre, D. etal. (2004) Anti-cyclic citrullinated peptide antibodies are highly associated with severe bone lesions in rheumatoid arthritis anti-CCP and bone damage in RA. Autoimmunity 37, 495-501.
78. Samanci, N., Ozdem, S., Akbas, H. etal. (2005) Diagnostic value and clinical significance of anti-CCP in patients with advanced rheumatoid arthritis. Journal of the National Medical Association 97, 1120-1126.
79. del Val del Amo, N., Ibanez Bosch, R., Fito Manteca, C. et al. (2006) Anti-cyclic citrullinated peptide antibody in rheumatoid arthritis: relation with disease aggressiveness. Clinical and Experimental Rheumatology 24, 281-286.
80. Korkmaz, C., Us, T., Kasifoglu, T. and Akgun, Y. (2006) Anti-cyclic citrullinated peptide (CCP) antibodies in patients with long-standing rheumatoid arthritis and their relationship with extra-articular manifestations. Clinical Biochemistry 39, 961-965.
81. Mewar, D., Coote, A., Moore, D.J. et al. (2006) Independent associations of anti-cyclic citrullinated peptide antibodies and rheumatoid factor with radiographic severity of rheumatoid arthritis. Arthritis Research and Therapy 8, R128.
82. Agrawal, S., Misra, R. and Aggarwal, A. (2007) Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA. Clinical Rheumatology 26, 201-204.
83. Zhao, Y., Tian, X. and Li, Z. (2007) Prevalence and clinical significance of antibodies to citrullinated fibrinogen (ACF) in Chinese patients with rheumatoid arthritis. Clinical Rheumatology 26, 1505-1512.
84. Munoz-Fernandez, S., Alvarez-Doforno, R., Gonzalez-Tarrio, J.M. et al. (1999) Antiperi-nuclear factor as a prognostic marker in rheumatoid arthritis. Journal of Rheumatology 26, 2572-2577.
85. Kroot, E.J., de Jong, B.A., van Leeuwen, M.A. et al. (2000) The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis and Rheumatism 43, 1831-1835.
86. Forslin, K., Vincent, C., Serre, G. and Svensson, B. (2001) Antifilaggrin antibodies in early rheumatoid arthritis may predict radiological progression. Scandinavian Journal of Rheumatol-ogy 30, 221-224.
87. Genevay, S., Hayem, G., Verpillat, P. and Meyer, O. (2002) An eight year prospective study of outcome prediction by antiperinuclear factor and antikeratin antibodies at onset ofrheumatoid arthritis. Annals of the Rheumatic Diseases 61, 734-736.
88. Meyer, O., Labarre, C., Dougados, M. et al. (2003) Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Annals of the Rheumatic Diseases 62, 120-126.
89. Vencovsky, J., Machacek, S., Sedova, L. et al. (2003) Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Annals of the Rheumatic Diseases 62, 427-430.
90. Forslind, K., Ahlmen, M., Eberhardt, K. et al. (2004) Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Annals of the Rheumatic Diseases 63, 1090-1095.
91. Lindqvist, E., Eberhardt, K., Bendtzen, K. et al. (2005) Prognostic laboratory markers of joint damage in rheumatoid arthritis. Annals of the Rheumatic Diseases 64, 196-201.
92. van der Helm-van Mil, A.H., Verpoort, K.N., Breedveld, F.C. et al. (2005) Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Research and Therapy 7, R949-R958.
93. Berglin, E., Johansson, T., Sundin, U. etal. (2006) Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Annals of the Rheumatic Diseases 65, 453-458.
94. Meyer, O., Nicaise-Roland, P., Santos, M.D. et al. (2006) Serial determination of cyclic citrullinated peptide autoantibodies predicted five-year radiological outcomes in a prospective cohort of patients with early rheumatoid arthritis. Arthritis Research and Therapy 8, R40.
95. Kaltenhauser, S., Pierer, M., Arnold, S. et al. (2007) Antibodies against cyclic citrullinated peptide are, associated with the DRB1 shared epitope and predict joint erosion in rheumatoid arthritis. Rheumatology (Oxford) 46, 100-104.
96. Innala, L., Kokkonen, H., Eriksson, C. et al. (2008) Antibodies against mutated citrullinated vimentin are a better predictor ofdisease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides. Journal of Rheumatology 35, 1002-1008.
97. Syversen, S.W., Gaarder, P.I., Goll, G.L. etal. (2008) High anti-cyclic citrullinated peptide levels and an algorithm offour variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Annals of the Rheumatic Diseases 67, 212-217.
98. Lundberg, K., Nijenhuis, S., Vossenaar, E.R. et al. (2005) Citrullinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severity. Arthritis Research and Therapy 7, R458-R467.
99. Kuhn, K.A., Kulik, L., Tomooka, B. et al. (2006) Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. Journal of Clinical Investigation 116, 961-973.
100. Vossenaar, E.R., Nijenhuis, S., Helsen, M.M. etal. (2003) Citrullination of synovial proteins in murine models of rheumatoid arthritis. Arthritis and Rheumatism 48, 2489-2500.
101. Vossenaar, E.R., van Boekel, M.A., van Venrooij, W.J. etal. (2004) Absence ofcitrulline-specific autoantibodies in animal models of autoimmunity. Arthritis and Rheumatism 50, 2370-2372.
102. Hill, J.A., Bell, D.A., Brintnell, W. et al. (2008) Arthritis induced by posttranslationally modified (citrullinated) fibrinogen in DR4-IE transgenic mice. Journal of Experimental Medicine 205, 967-979.
103. Vincent, C., Serre, G., Basile, J.P. etal. (1990) Subclass distribution of IgGs antibodies to the rat oesophagus stratum corneum (so-called anti-keratin antibodies) in rheumatoid arthritis. Clinical and Experimental Immunology 81, 83-89.
104. Chapuy-Regaud, S., Nogueira, L., Clavel, C. et al. (2005) IgGs subclass distribution of the rheumatoid arthritis-specific autoantibodies to citrullinated fibrin. Clinical and Experimental Immunology 139, 542-550.
105. Clavel, C., Nogueira, L., Laurent, L. et al. (2008) Induction of macrophage secretion of tumor necrosis factor alpha through Fcgamma receptor IIa engagement by rheumatoid arthritis-specific autoantibodies to citrullinated proteins complexed with fibrinogen. Arthritis and Rheumatism 58, 678-688.
106. Feldmann, M., Brennan, F.M. and Maini, R.N. (1996) Role of cytokines in rheumatoid arthritis. Annual Review of Immunology 14, 397-440.
107. Feldmann, M. and Maini, R.N. (2001) Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annual Review of Immunology 19, 163-196.
108. Boross, P. and Verbeek, J.S. (2006) The complex role of Fcgamma receptors in the pathology of arthritis. Springer Seminars in Immunopathology 28 339-350.
109. Despres, N., Boire, G., Lopez-Longo, F.J. and Menard, H.A. (1994) TheSasystem: a novel antigen-antibody system specific for rheumatoid arthritis. Journal of Rheumatology 21, 1027-1033.
110. Vossenaar, E.R., Despres, N., Lapointe, E. et al. (2004) Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Research and Therapy 6, R142-R150.
111. Menard, H.A., Lapointe, E., Rochdi, M.D. and Zhou, Z.J. (2000) Insights into rheumatoid arthritis derived from the Sa immune system. Arthritis Research 2, 429-432.
112. Nijenhuis, S., Zendman, A.J., Vossenaar, E.R. et al. (2004) Autoantibodies to citrullinated proteins in rheumatoid arthritis: clinical performance and biochemical aspects ofan RA-specific marker. Clinica Chimica Acta 350, 17-34.
113. Cantaert, T., De Rycke, L., Bongartz, T. et al. (2006) Citrullinated proteins in rheumatoid arthritis: crucial... but not sufficient! Arthritis and Rheumatism 54, 3381-3389.
114. Asaga, H., Yamada, M. and Senshu, T. (1998) Selective deimination of vimentin in calcium ionophore-induced apoptosis of mouse peritoneal macrophages. Biochemical and Biophysical Research, Communications 243, 641-646.
115. Bang, H., Egerer, K., Gauliard, A. etal. (2007) Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis and Rheumatism 56, 2503-2511.
116. Mathsson, L., Mullazehi, M., Wick, M.C. et al. (2008) Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis and Rheumatism 58, 36-45.
117. Dejaco, C., Klotz, W., Larcher, H. et al. (2006) Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis. Arthritis Research and Therapy 8, R119.
118. Sghiri, R., Bouagina, E., Zaglaoui, H. et al. (2007) Diagnostic performances of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis. Rheumatology International 27, 1125-1130.
119. Tilleman, K., Van Steendam, K., Cantaert, T. et al. (2008) Synovial detection and autoantibody reactivity of, processed citrullinated isoforms of vimentin in inflammatory arthritides. Rheumatology (Oxford) 47, 597-604.
120. Suzuki, A., Yamada, R., Ohtake-Yamanaka, M. et al. (2005) Anti-citrullinated collagen type I antibody is a target of autoimmunity in rheumatoid arthritis. Biochemical and Biophysical Research, Communications 333, 418-426.
121. Burkhardt, H., Sehnert, B., Bockermann, R. et al. (2005) Humoral immune response to citrullinated collagen type II determinants in early rheumatoid arthritis. European Journal of Immunology 35, 1643-1652.
122. Koivula, M.K., Aman, S., Karjalainen, A. etal. (2005) Are there autoantibodies reacting against citrullinated peptides derived from type I and type II collagens in patients with rheumatoid arthritis? Annals of the Rheumatic Diseases 64, 1443-1450.
123. Yoshida, M., Tsuji, M., Kurosaka, D. etal. (2006) Autoimmunityto citrullinated type II collagen in rheumatoid arthritis. Modern Rheumatology 16, 276-281.
124. Koivula, M.K., Ramberg, J., Aman, S. et al. (2005) Sensitive immunoassays for the autoantibodies reacting against citrullinated carboxy-terminal telopeptides of type I and type II collagens in patients with rheumatoid arthritis. Clinical Chemistry and Laboratory Medicine 43, 1400-1405.
125. Koivula, M.K., Aman, S., Alasaarela, E. et al. (2006) Inhibitory characteristics of citrullinated telopeptides, of type I and II collagens for autoantibody binding in patients with rheumatoid arthritis. Rheumatology (Oxford) 45, 1364-1369.
126. Koivula, M.K., Heliovaara, M., Ramberg, J. etal. (2007) Autoantibodies binding to citrullinated telopeptide of type II collagen and to cyclic citrullinated peptides predict synergistically the development of seropositive rheumatoid arthritis. Annals of the Rheumatic Diseases 66, 1450-1455.
127. Koivula, M.K., Savolainen, E., Kaipiainen-Seppanen, O. et al. (2008) Sensitivity and specificity of autoantibodies binding, to citrullinated carboxyterminal telopeptides of types I and II collagens in an early arthritis series. Rheumatology (Oxford) 47, 656-659.
128. Matsuo, K., Xiang, Y., Nakamura, H. et al. (2006) Identification of novel citrullinated autoantigens of synovium in rheumatoid arthritis using a proteomic approach. Arthritis Research and Therapy 8, R175.
129. Skriner, K., Adolph, K., Jungblut, P.R. and Burmester, G.R. (2006) Association of citrullinated proteins with synovial exosomes. Arthritis and Rheumatism 54, 3809-3814.
130. Hill, J.A., Al-Bishri, J., Gladman, D.D. etal. (2006) Serum autoantibodies that bind citrullinated fibrinogen are frequently found in patients with rheumatoid arthritis. Journal of Rheumatology 33, 2115-2119.
131. Sebbag, M., Moinard, N., Auger, I. et al. (2006) Epitopes of human fibrin recognized by the rheumatoid arthritis-specific autoantibodies to citrullinated proteins. European Journal of Immunology 36, 2250-2263.
132. Weinberg, J.B., Pippen, A.M. and Greenberg, C.S. (1991) Extravascular fibrin formation and dissolution in synovial tissue of patients with osteoarthritis and rheumatoid arthritis. Arthritis and Rheumatism 34, 996-1005.
133. Busso, N. and Hamilton, J.A. (2002) Extravascular coagulation and the plasminogen activator/plasmin system in rheumatoid arthritis. Arthritis and Rheumatism 46, 2268-2279.
134. Suzuki, A., Yamada, R., Chang, X. et al. (2003) Functional haplotypes of PAD14, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nature Genetics 34, 395-402.
135. Nakayama-Hamada, M., Suzuki, A., Kubota, K. et al. (2005) Comparison of enzymatic properties between hPAD12 and hPAD14. Biochemical and Biophysical Research, Communications 327, 192-200.
136. De Rycke, L., Nicholas, A.P., Cantaert, T. et al. (2005) Synovial intracellular citrullinated proteins colocalizing with peptidyl arginine deiminase as pathophysiologically relevant anti-genic determinants of rheumatoid arthritis-specific humoral autoimmunity. Arthritis and Rheumatism 52, 2323-2330.
137. Chang, X., Yamada, R., Suzuki, A. et al. (2005) Citrullination of fibronectin in rheumatoid arthritis, synovial tissue. Rheumatology (Oxford) 44, 1374-1382.
138. Verpoort, K.N., Jol-van der Zijde, C.M., Papendrecht-van der Voort, E.A. et al. (2006) Isotype distribution of anti-cyclic citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response. Arthritis and Rheumatism 54, 3799-3808.
139. Hida, S., Miura, N.N., Adachi, Y. and Ohno, N. (2004) Influence of arginine deimination on antigenicity of fibrinogen. Journal of Autoimmunity 23, 141-150.
140. Duplan, V., Foulquier, C., Clavel, C. etal. (2006) In the rat, citrullinated autologous fibrinogen is immunogenic but the induced autoimmune response is not arthritogenic. Clinical and Experimental Immunology 145, 502-512.
141. Rubin, B. and Matron, C. (2005) Themouseimmuneresponsetohumanfibrinogenrevealsan autoimmune component against mouse fibrinogen. Cellular Immunology 233, 41-52.
142. Vossenaar, E.R., Smeets, T.J., Kraan, M.C. et al. (2004) The presence of citrullinated proteins is not specific for rheumatoid synovial tissue. Arthritis and Rheumatism 50, 3485-3494.
143. Makrygiannakis, D., af Klint, E., Lundberg, I.E. et al. (2006) Citrullination is an inflammationdependent process. Annals of the Rheumatic Diseases 65, 1219-1222.
144. Bongartz, T., Cantaert, T., Atkins, S.R. et al. (2006) Citrullination in extra-articular manifestations of, rheumatoid arthritis. Rheumatology (Oxford) 46, 70-75.
145. Baeten, D., Peene, I., Union, A. et al. (2001) Specific presence of intracellular citrullinated proteins in rheumatoid arthritis synovium: relevance to antifilaggrin autoantibodies. Arthritis and Rheumatism 44, 2255-2262.
146. Baeten, D., Kruithof, E., De Rycke, L. et al. (2004) Diagnostic classification of spondylarthro-pathy and rheumatoid arthritis by synovial histopathology: a prospective study in 154 consecutive patients. Arthritis and Rheumatism 50, 2931-2941.
147. Stastny, P. (1978) Association of the B-cell alloantigen DRw4 with rheumatoid arthritis. New England Journal of Medicine 298, 869-871.
148. Wordsworth, B.P., Lanchbury, J.S., Sakkas, L.I. et al. (1989) HLA-DR4 subtype frequencies in rheumatoid, arthritis indicate that DRB1 is the major susceptibility locus within the HLA class II region. Proceedings of the National Academy of Sciences USA 86, 10049-10053.
149. Gregersen, P.K., Silver, J. and Winchester, R.J. (1987) The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis and Rheumatism 30, 1205-1213.
150. Forslin, K., Vincent, C., Serre, G. and Svensson, B. (2000) Antifilaggrin autoantibodies in early rheumatoid arthritis. Scandinavian Journal of Rheumatology 29, 320-322.
151. Bas, S., Perneger, T.V., Mikhnevitch, E. etal. (2000) Association of rheumatoid factors and anti-filaggrin, antibodies with severity of erosions in rheumatoid arthritis. Rheumatology (Oxford) 39, 1082-1088.
152. Auger, I., Sebbag, M., Vincent, C. etal. (2005) Influence of HLA-DRgenes on the production of rheumatoid arthritis-specific autoantibodies to citrullinated fibrinogen. Arthritis and Rheumatism 52, 3424-3432.
153. Huizinga, T.W., Amos, C.I., van der Helm-van Mil, A.H. et al. (2005) Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis and Rheumatism 52, 3433-3438.
154. van der Helm-van Mil, A.H., Verpoort, K.N., Breedveld, F.C. et al. (2006) The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. Arthritis and Rheumatism 54, 1117-1121.
155. Klareskog, L., Stolt, P., Lundberg, K. et al. (2006) A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis and Rheumatism 54, 38-46.
156. Hill, J.A., Southwood, S., Sette, A. et al. (2003) Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. Journal of Immunology 171, 538-541.
157. Ireland, J., Herzog, J. and Unanue, E.R. (2006) Cutting edge: unique T cells that recognize citrullinated peptides are a feature of protein immunization. Journal of Immunology 177, 1421-1425.
158. Vang, T., Miletic, A.V., Arimura, Y. et al. (2008) Protein tyrosine phosphatases in autoimmu-nity. Annual Review of Immunology 26, 29-55.
159. Wesoly, J., van der Helm-van Mil, A.H., Toes, R.E. et al. (2005) Association of the PTPN22 C1858T single-nucleotide polymorphism with rheumatoid arthritis phenotypes in an inception cohort. Arthritis and Rheumatism 52, 2948-2950.
160. Johansson, M., Arlestig, L., Hallmans, G. and Rantapaa-Dahlqvist, S. (2006) PTPN22 polymorphism and anti-cyclic citrullinated peptide antibodies in combination strongly predicts future onset of rheumatoid arthritis and has a specificity of 100% for the disease. Arthritis Research and Therapy 8, R19.
161. Kokkonen, H., Johansson, M., Innala, L. etal. (2007) The PTPN22 1858C/T polymorphism is associated with anti-cyclic citrullinated peptide antibody-positive early rheumatoid arthritis in northern Sweden. Arthritis Research and Therapy 9, R56.
162. Karlson, E.W., Chibnik, L.B., Cui, J. et al. (2008) Associations between human leukocyte antigen, PTPN22, CTLA4 genotypes and rheumatoid arthritis phenotypes of autoantibody status, age at diagnosis and erosions in a large cohort study. Annals of the Rheumatic Diseases 67, 358-363.
163. Ikari, K., Kuwahara, M., Nakamura, T. etal. (2005) Association between PAD14 and rheumatoid arthritis: a replication study. Arthritis and Rheumatism 52, 3054-3057.
164. Kang, C.P., Lee, H.S., Ju, H. etal. (2006) A functional haplotype of the PAD14 gene associated with increased rheumatoid arthritis susceptibility in Koreans. Arthritis and Rheumatism 54, 90-96.
165. Plenge, R.M., Padyukov, L., Remmers, E.F. etal. (2005) Replication of putative candidate-gene associations with rheumatoid arthritis in ≥4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PAD14. American Journal of Human Genetics 77, 1044-1060.
166. Hoppe, B., Haupl, T., Gruber, R. et al. (2006) Detailed analysis of the variability of peptidy-larginine deiminase type 4 in German patients with rheumatoid arthritis: a case-control study. Arthritis Research and Therapy 8, R34.
167. Barton, A., Bowes, J., Eyre, S. etal. (2004) A functional haplotype of the PAD14 gene associated with rheumatoid arthritis in a Japanese population is not associated in a United Kingdom population. Arthritis and Rheumatism 50, 1117-1121.
168. Harney, S.M., Meisel, C., Sims, A.M. et al. (2005) Genetic and genomic studies of PAD14 in, rheumatoid arthritis. Rheumatology (Oxford) 44, 869-872.
169. Martinez, A., Valdivia, A., Pascual-Salcedo, D. et al. (2005) PAD14 polymorphisms are not associated with, rheumatoid arthritis in the Spanish population. Rheumatology (Oxford) 44, 1263-1266.
170. Caponi, L., Petit-Teixeira, E., Sebbag, M. et al. (2005) A family based study shows no association between rheumatoid arthritis and the PAD14 gene in a white French population. Annals of the Rheumatic Diseases 64, 587-593.
171. Suzuki, M., Miyagi, J., Kuribayashi, M. etal. (2006) Evaluationofallelefrequencies in the PAD14 gene and anti-cyclic citrullinated peptide antibodies of patients with rheumatoid arthritis in a Japanese population. Annals of the Rheumatic Diseases 65, 1399-1400.
172. Cha, S., Choi, C.B., Han, T.U. et al. (2007) Association of anti-cyclic citrullinated peptide antibody levels with PAD14 haplotypes in early rheumatoid arthritis and with shared epitope alleles in very late rheumatoid arthritis. Arthritis and Rheumatism 56, 1454-1463.
173. Oliver, J.E. and Silman, A.J. (2006) Risk factors for the development of rheumatoid arthritis. Scandinavian Journal of Rheumatology 35, 169-174.
174. van der Helm-van Mil, A.H., Verpoort, K.N., le Cessie, S. et al. (2007) The HLA-DRB1 shared epitope alleles differ in the interaction with smoking and predisposition to antibodies to cyclic citrullinated peptide. Arthritis and Rheumatism 56, 425-432.
175. Pedersen, M., Jacobsen, S., Garred, P. etal. (2007) Strong combined gene-environment effects in anti-cyclic citrullinated peptide-positive rheumatoid arthritis: a nationwide case-control study in Denmark. Arthritis and Rheumatism 56, 1446-1453.
176. Lee, H.S., Irigoyen, P., Kern, M. etal. (2007) Interaction between smoking, the shared epitope, and anti-cyclic citrullinated peptide: a mixed picture in three large North American rheumatoid arthritis cohorts. Arthritis and Rheumatism 56, 1745-1753.
177. Mikuls, T.R., Hughes, L.B., Westfall, A.O. et al. (2008) Cigarette smoking, disease severity, and autoantibody expression in African Americans with recent-onset rheumatoid arthritis. Annals of the Rheumatic Diseases 67, 1529-1534.
178. Klareskog, L., Ronnelid, J., Lundberg, K. et al. (2008) Immunity to citrullinated proteins in rheumatoid arthritis. Annual Review of Immunology 26, 651-675.
179. Makrygiannakis, D., Hermansson, M., Ulfgren, A.K. et al. (2008) Smoking increases peptidy-larginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells. Annals of the Rheumatic Diseases 67, 1488-1492.
180. Balandraud, N., Roudier, J. and Roudier, C. (2004) Epstein-Barr virus and rheumatoid arthritis. Autoimmunity Reviews 3, 362-367.
181. Anzilotti, C., Merlini, G., Pratesi, F. et al. (2006) Antibodies to viral citrullinated peptide in rheumatoid arthritis. Journal of Rheumatology 33, 647-651.
182. Pratesi, F., Tommasi, C., Anzilotti, C. et al. (2006) Deiminated Epstein-Barr virus nuclear antigen 1 is a target of anti-citrullinated protein antibodies in rheumatoid arthritis. Arthritis and Rheumatism 54, 733-741.
183. Kinloch, A., Tatzer, V., Wait, R. et al. (2005) Identification of citrullinated alpha-enolase as a candidate autoantigen in rheumatoid arthritis. Arthritis Research and Therapy 7, R1421-R1429.